Skip to main content

View full-text article in PMC

. 2017 May 20;8(57):96684–96696. doi: 10.18632/oncotarget.18042

Table 5. Concomitant BRAF mutation and activating KRAS mutation in lung cancers.

mut 1 (VAF%)	mut 2 (VAF%)	BRAF kinase activity
KRAS p.Q61H (12%)	BRAF p.G464V (9.5%)	activated^a [19]
KRAS p.G12D (19%)	BRAF p.G466E (3.3%)	Impaired [19]
KRAS p.A146T (30%)	BRAF p.G466V (35%)	Impaired [19]
KRAS p.G12D (19%)	BRAF p.G466V (14%)	Impaired [19]
KRAS p.G12V (14%)	BRAF p.D594G (2.6%)	Impaired [20]
KRAS p.Q61H (24%)^b	BRAF p.D594N (5.7%)^b	Impaired [21]
KRAS p.G12V (16%) ^b	BRAF p.T440I (13%)^b	unknown
KRAS p.G12C (14%)	BRAF p.G466L (12%)	unknown
KRAS p.G12R (12%)^b	BRAF p.G469R (11%)^b	unknown
KRAS p.G13D (25%)^b	BRAF p.G469V (20%)^b	unknown
KRAS p. A146T (11%)	BRAF p.K601N (11%)	unknown

VAF: variant allele frequency.

^aCategorized as intermediate activity mutants by Wan et al. [19].

^bThese 4 cases have been reported previously [22].